Navigation Links
Former Pfizer Inc. Senior Director Joins Growing MusclePharm Medical Advisory Board

DENVER, April 11, 2011 /PRNewswire/ -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: MSLP), an expanding U.S. nutritional supplement company, is pleased to announce the addition of Richard Ogden, PhD, to its medical advisory board.

"It is a great honor to welcome Dr. Ogden to the MusclePharm team," stated Cory Gregory, President of MusclePharm.  "Dr. Ogden's extensive knowledge and experience in launching HIV medications for global pharmaceutical companies offers MusclePharm a considerable benefit as we venture into the clinical realm of therapeutic nutritional supplementation with our innovative whey protein product, MuscleGel®. We believe Dr. Ogden's expertise will help lead the way as we explore the various opportunities in the medical application of MusclePharm's products."

MusclePharm is presently seeking Medicaid reimbursement for MuscleGel®, beginning with the State of New York.  MuscleGel® is a unique whey protein supplement gel formulated to assist in the treatment and prevention of muscle loss in HIV patients.  Following a successful meeting with New York Office of Health Insurance Policy representatives in Albany on March 28, 2011, the Company is currently gathering the necessary documentation to submit to Medicaid officials over the next several weeks to finalize the Medicaid approval process for MuscleGel® reimbursement.

Dr. Ogden is the co-founder of RORR Inc. ("RORR"), a medical, scientific consulting and educational company focused on viral infectious diseases, including HIV, and the incorporation of strategic planning for clinical research programs and product development in the antiviral and oncology therapeutic areas.  Clients of RORR include fledgling pharmaceutical and biotechnology companies that are developing innovative HIV treatments, as well as the International AIDS society.

Prior to his tenure at RORR, Dr. Ogden spent considerable time in a variety of roles at Agouron Pharmaceuticals, Inc. ("Agouron"), before it was acquired by Pfizer Inc. in 2001.  His career at Agouron began with his role as a Senior Scientist before successful terms as a Group Leader in Medicinal Chemistry, Principal Scientist and Manager of New Projects Research and, ultimately, as the Director of Scientific Development.

Dr. Ogden was a team member in the discovery and development of the early protease inhibitor Nelfinavir (Viracept®).  He assisted in the clinical launch of Nelfinavir (Viracept®), providing medical education in the HIV/AIDS clinical and patient communities, along with the evaluation of proposals for post marketing clinical research in the HIV/AIDS area.

Dr. Ogden held the position of Senior Director of Scientific Affairs, HIV, for Pfizer Inc.  He also supported the pre-marketing activities for many other clinical agents in the HIV/AIDS and oncology therapeutic areas.  Additionally, Dr. Ogden served as a representative on the International AIDS Society Industry Liaison Forum.

"Following data released at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in March 2, 2011, the need to sustain muscle mass in patients with HIV and AIDS is more evident now than ever," continued Mr. Gregory.  "The FRAM study (Fat Redistribution and Metabolic Change in HIV Infection) concluded that lower leg and arm muscle mass, as well as higher abdominal visceral fat, equate to shorter survival in people living with HIV and AIDS.  A variety of pharmaceutical options exist to build muscle mass but additional options are needed due to detrimental factors with these therapies such as high cost, toxicities, routes of administration (intramuscular injections) and side effects.  MuscleGel® offers a simple, low cost, easy to use alternative for not only helping to treat but assisting in the prevention of muscle loss.  We believe that Dr. Ogden will be fundamental in assisting and directing us in our pursuit to make MuscleGel® available to HIV patients worldwide."

Dr. Ogden has written for numerous scientific and educational publications.  He has also co-edited a book on Protease Inhibitors in AIDS Therapy and a book on Reverse Transcriptase Inhibitors in AIDS Therapy as well.  Dr. Ogden received his MA in Chemistry and a PhD in Organic Chemistry from Cambridge University in England.

About MusclePharm Corporation

Headquartered in Denver, Colorado, MusclePharm is a healthy life-style company that develops and manufactures a full line of National Science Foundation approved nutritional supplements that are 100% free of banned substances.  Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues, including the National Football League, Mixed Martial Arts, and Major League Baseball.  The Company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.  MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe.  MusclePharm products are also sold in over 100 online stores, including, and  For more information, please visit

Forward Looking Statements  

The information contained herein includes forward-looking statements.  These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity.  We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Contact:
Cory Gregory

SOURCE MusclePharm Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
2. Former PayPal, Palantir Executive Jason Portnoy Joins Practice Fusion as CFO
3. Erica L. Mann, Former Pfizer Executive, Appointed New President of Bayer HealthCares Global Consumer Care Division
4. Governor Corbett Announces at Least 80 New Jobs in Lehigh Valley with Pharmaceutical Companys Purchase, Renovation of Former Amcor Site
5. 2P2D Ltd. Announces the Appointment of Tovi Bachar, Former Managing Director of GE Healthcare Israel, as Director and Chairman
6. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
7. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
8. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
9. CVS Caremark Customer Care Team Awarded Silver Medal for Best Customer Service at Contact Center Worlds Global Top Ranking Performers Conference
10. Governor Michael O. Leavitt, Former HHS Secretary and EPA Administrator, Selects WorldWide Speakers Group for Exclusive Representation
11. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
Post Your Comments:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... 2016 Global Cervical Dysplasia Market: Scope ... cervical dysplasia market analyzes the current and future ... elaborate executive summary, including a market snapshot that ... The research is a combination of primary ... of our research efforts along with information collected ...
(Date:12/7/2016)... , Dec. 7, 2016 REPORT ... Market Intelligence (2011-2020)" provides market intelligence on a ... forecast (2011-2020) has been provided in the report. ... provide 1) comprehensive global market intelligence through detailed ... market dynamics, industry structure and developments, market situation, ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... They are ... are sisters and wives, brothers and fathers, from New England and around the nation. ... its stigma, and are brought together in a beautiful and compelling new photographic exhibit ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
Breaking Medicine News(10 mins):